Bartomeu Massutí

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal et al. · Journal of Clinical Oncology · 2022 · 335 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial

Carlos Camps, Bartomeu Massutí, Ángel Martín Jiménez et al. · Annals of Oncology · 2005 · 130 citations

Medicine, Oncology, Pharmacotherapy +11

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim et al. · Journal of Clinical Oncology · 2024 · 114 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Ernest Nadal, Delvys Rodríguez‐Abreu, Marta Simó et al. · Journal of Clinical Oncology · 2023 · 106 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Lung cancer symptoms at diagnosis: results of a nationwide registry study

Alberto Ruano‐Raviña, Enric Carcereny, Teresa Morán et al. · ESMO Open · 2020 · 78 citations · Full text

Medicine, Oncology, Cancer Epidemiology +15